Some big names reported after the bell today, namely Intel, Yahoo and Motorola, but these earnings posts will focus on some of the more obscure fast growing companies that don’t get the coverage. Again, SelfInvestors.com fundamental rank in brackets.

Gilead Sciences (GILD) [28/30]

The highest rated company reporting after the bell today with a SelfInvestors.com fundamental rank of 28/30 is Gilead Sciences (GILD).  This is a company that just consistently keeps posting solid growth every quarter.  This time around the company reported earnings of .38/share on revenue of growth of 493.5 million, good for growth of 52% and 51% respectively over the year ago quarter, which beat analyst expectations of .36/share and the "whisper number" of .37/share.

Highlights:

• Sales of its new HIV drug Truvada grew 32%
• Sales of its Hepititus B drug Hepsera grew 58%
• Royalties earned on its antiviral drug Tamiflu, which countries have been stockpiling due to the potential of an avian bird flu outbreak soared to 12.1 mill, from 1.7mill in the year ago period (note: Gilead said Roche had breached the companies’ Tamiflu marketing agreement. The companies were unable to resolve the dispute and are currently in arbitration)
• Company raised its outlook for 2005 sales of its HIV drugs

The stock is down a bit after hours.  Technically, it continues to look very strong despite a tough market.  It broke out of a base on 9/30 and remains in a buyable range.

USANA Health Sciences (USNA) [27/30]

USANA posted another good quarter but it wasn’t exceptional by any means.  The company beat analyst estimates with earnings growth of 31% on revenue growth of 20%, but that marks the 7th straight quarter of declining year over year revenue growth.  It appears the high growth days are over.  The company said 2006 revenue growth would be in the range of 15 – 20%.  A breakout of the stock failed at the end of September and has slipped back into a base, but above the 200 day moving average.  It’s trading down a bit after hours.